Deal flow picked up last week with ten IPOs pricing and raising almost $1.9 billion in proceeds. Though it was a strong week for pricings, six of the ten deals slashed their valuations in order to complete their offerings, and all five deals that priced on...read more
Esperion Therapeutics, which is developing a treatment for elevated levels of low-density lipoprotein cholesterol, raised $70 million by offering 5.0 million shares at $14, within the range of $13 to $15. Esperion Therapeutics plans to list on the NASDAQ under...read more
For the fifth consecutive week, at least one US IPO gained 30%, as Gigamon (GIMO) climbed nearly 50%. The week's most prominent IPO, Coty (COTY), faltered though, and the third scheduled deal, Aratana Therapeutics (PETX) was delayed. Nine more IPOs,...read more
Esperion Therapeutics, a biotech focused on developing a treatment for patients with elevated levels of low-density lipoprotein cholesterol, announced terms for its IPO on Wednesday. The Plymouth, MI-based company plans to raise $63 million by offering 4.5...read more
US IPO Recap: Market picks up the pace with ten IPOs, six price below the range
Deal flow picked up last week with ten IPOs pricing and raising almost $1.9 billion in proceeds. Though it was a strong week for pricings, six of the ten deals slashed their valuations in order to complete their offerings, and all five deals that priced on...read more
Esperion Therapeutics prices upsized IPO at $14, the midpoint of the range
Esperion Therapeutics, which is developing a treatment for elevated levels of low-density lipoprotein cholesterol, raised $70 million by offering 5.0 million shares at $14, within the range of $13 to $15. Esperion Therapeutics plans to list on the NASDAQ under...read more
US IPO Recap: Coty fades, Gigamon springs and 17 companies file or set terms
For the fifth consecutive week, at least one US IPO gained 30%, as Gigamon (GIMO) climbed nearly 50%. The week's most prominent IPO, Coty (COTY), faltered though, and the third scheduled deal, Aratana Therapeutics (PETX) was delayed. Nine more IPOs,...read more
Biotech Esperion Therapeutics sets terms for $63 million IPO
Esperion Therapeutics, a biotech focused on developing a treatment for patients with elevated levels of low-density lipoprotein cholesterol, announced terms for its IPO on Wednesday. The Plymouth, MI-based company plans to raise $63 million by offering 4.5...read more